Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 185

Sort by

Sort Order Select

Journal Articles

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Blood (2023) 141 (17): 2047–2061.

https://doi.org/10.1182/blood.2022018604

Published: 2023

Includes: Supplemental data

Journal Articles

DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with SF3B1 Mutation

Blood (2022) 140 (Supplement 1): 215–216.

https://doi.org/10.1182/blood-2022-164584

Published: 2022

Journal Articles

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 1121–1124.

https://doi.org/10.1182/blood-2022-163634

Published: 2022

Journal Articles

Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories

Blood (2022) 140 (Supplement 1): 6976–6978.

https://doi.org/10.1182/blood-2022-158671

Published: 2022

Journal Articles

Characteristics of Germline CHEK2 Mutated Patients in a Large Cohort of 2322 Myeloid Malignancies

Lucie Freiman, Lise Larcher, Giulia Tueur, Nadia Vasquez, Mélanie Da Costa, Emmanuel Raffoux, Lionel Ades, Pierre Fenaux, Jean Soulier, Emmanuelle Clappier, Raphael Itzykson

Blood (2022) 140 (Supplement 1): 4082–4083.

https://doi.org/10.1182/blood-2022-158799

Published: 2022

Journal Articles

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

Blood (2022) 140 (Supplement 1): 12335–12338.

https://doi.org/10.1182/blood-2022-163478

Published: 2022

Journal Articles

The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Blood (2022) 140 (Supplement 1): 2887–2890.

https://doi.org/10.1182/blood-2022-162367

Published: 2022

Journal Articles

Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Maria Sirenko, Elsa Bernard, David B. Beck, Maria Creignou, Dylan Domenico, Andrea Farina, Juan E Arango, Olivier Kosmider, Robert P. Hasserjian, Martin Jadersten, Ulrich Germing, Guillermo Sanz, Arjan A. van de Loosdrecht, Matilde Y Follo, Felicitas R. Thol, Lurdes Zamora, Ronald Feitosa Pinheiro, Andrea Pellagatti, Harold K. Elias, Detlef Haase, Christina Ganster, Lionel Ades, Magnus Tobiasson, Laura Palomo, Matteo G. Della Porta, Kety Huberman, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia M. Klimek, Fabio Pires de Souza Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Seishi Ogawa, Michaela Fontenay, Joop H. Jansen, Jose Cervera, Benjamin L. Ebert, Rafael Bejar, Peter L Greenberg, Norbert Gattermann, Luca Malcovati, Mario Cazzola, Eva Hellström-Lindberg, Elli Papaemmanuil

Blood (2022) 140 (Supplement 1): 9785–9788.

https://doi.org/10.1182/blood-2022-162397

Published: 2022

Journal Articles

Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

Blood (2022) 140 (7): 756–768.

https://doi.org/10.1182/blood.2021015328

Published: 2022

Includes: Supplemental data

Journal Articles

Clinical, pathological, and molecular features of myelodysplasia cutis

Jérémie Delaleu, Rathana Kim, Lin-Pierre Zhao, Adèle de Masson, Marie-Dominique Vignon-Pennamen, Charles Cassius, Caroline Ram-Wolff, Martine Bagot, Emmanuelle Clappier, Lionel Adès, Marie Sebert, Jean-David Bouaziz, Pierre Fenaux, Maxime Battistella

Blood (2022) 139 (8): 1251–1253.

https://doi.org/10.1182/blood.2021013967

Published: 2022

Includes: Supplemental data

Journal Articles

A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial)

Blood (2021) 138 (Supplement 1): 3697.

https://doi.org/10.1182/blood-2021-150904

Published: 2021

Journal Articles

Genomic Landscape and Clinical Features of Myeloproliferative Neoplasm (MPN) Patients with Auto-Immune and Inflammatory Diseases (AID)

Dikelele Elessa, Lin-Pierre Zhao, Rafael Daltro De Oliveira, Nabih Maslah, Juliette Soret-Dulphy, Emmanuelle Verger, Clemence Marcault, Nathalie Parquet, Pierre Fenaux, Lionel Ades, Emmanuel Raffoux, Stephane Giraudier, Olivier Fain, Bruno Cassinat, Jean-Jacques Kiladjian, Arsene Mekinian, Lina Benajiba

Blood (2021) 138 (Supplement 1): 1496.

https://doi.org/10.1182/blood-2021-152302

Published: 2021

Journal Articles

Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group

Blood (2021) 138 (Supplement 1): 62.

https://doi.org/10.1182/blood-2021-146932

Published: 2021

Journal Articles

Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group

Blood (2021) 138 (Supplement 1): 63.

https://doi.org/10.1182/blood-2021-147898

Published: 2021

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk"

Blood (2021) 138 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2021-146846

Published: 2021

Journal Articles

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

Mikkael A. Sekeres, Larisa Girshova, Vadim A Doronin, Maria Diez-Campelo, David Valcarcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Douglas V. Faller, Lionel Ades

Blood (2021) 138 (Supplement 1): 242.

https://doi.org/10.1182/blood-2021-146154

Published: 2021

Journal Articles

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Blood (2021) 138 (Supplement 1): 246.

https://doi.org/10.1182/blood-2021-153286

Published: 2021

Journal Articles

Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study

Blood (2021) 138 (Supplement 1): 2158.

https://doi.org/10.1182/blood-2021-146254

Published: 2021

Journal Articles

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Blood (2021) 138 (7): 507–519.

https://doi.org/10.1182/blood.2021011103

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

Blood (2021) 137 (20): 2827–2837.

https://doi.org/10.1182/blood.2020010165

Published: 2021

Includes: Supplemental data

NARROW

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with SF3B1 Mutation

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories

Characteristics of Germline CHEK2 Mutated Patients in a Large Cohort of 2322 Myeloid Malignancies

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

Clinical, pathological, and molecular features of myelodysplasia cutis

A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial)

Genomic Landscape and Clinical Features of Myeloproliferative Neoplasm (MPN) Patients with Auto-Immune and Inflammatory Diseases (AID)

Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group

Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group

Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk"

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only